Literature DB >> 12414916

Atheroprotective effects of high-density lipoproteins.

Gerd Assmann1, Jerzy-Roch Nofer.   

Abstract

Observational studies provide overwhelming evidence that a low high-density lipoprotein (HDL)-cholesterol level increases the risk of coronary events, both in healthy subjects and in patients with coronary heart disease. Based on in vitro experiments, several mechanistic explanations for the atheroprotective function of HDL have been suggested. However, few of these were verified in vivo in humans or in experiments with transgenic animals. The HDL functions currently most widely held to account for the antiatherogenic effect include participation in reverse cholesterol transport, protection against endothelial dysfunction, and inhibition of oxidative stress. This review summarizes current views on the molecular mechanism underlying these atheroprotective effects of HDL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12414916     DOI: 10.1146/annurev.med.54.101601.152409

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  57 in total

Review 1.  Genetics of cholesterol efflux.

Authors:  Iulia Iatan; Aurélien Palmyre; Sarah Alrasheed; Isabelle Ruel; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs.

Authors:  C Muller; R Salvayre; A Nègre-Salvayre; C Vindis
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

3.  High density lipoprotein mediated lipid efflux from retinal pigment epithelial cells in culture.

Authors:  B Y Ishida; K G Duncan; K R Bailey; J P Kane; D M Schwartz
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  Maternal plasma cholesterol and duration of pregnancy: A prospective cohort study in Ghana.

Authors:  Brietta M Oaks; Christine P Stewart; Kevin D Laugero; Seth Adu-Afarwuah; Anna Lartey; Stephen A Vosti; Per Ashorn; Kathryn G Dewey
Journal:  Matern Child Nutr       Date:  2016-12-27       Impact factor: 3.092

Review 5.  Microvesicles: potential markers and mediators of endothelial dysfunction.

Authors:  Ming-Lin Liu; Kevin Jon Williams
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

6.  Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI.

Authors:  Manojkumar Valiyaveettil; Niladri Kar; Mohammad Z Ashraf; Tatiana V Byzova; Maria Febbraio; Eugene A Podrez
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

7.  Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.

Authors:  Ayman A Hussein; Stephen J Nicholls
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

8.  A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity.

Authors:  Tiffany L Graves; John E Scott
Journal:  Curr Chem Genomics       Date:  2008-11-26

9.  Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats.

Authors:  Chia Hui Apphia Eu; Wai Yen Alfred Lim; So Ha Ton; Khalid bin Abdul Kadir
Journal:  Lipids Health Dis       Date:  2010-07-29       Impact factor: 3.876

Review 10.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.